B-LCL-HROC173

302039

□□

□□

□□□□□□CRC□□□□□□□□□□□□□

□□□□□	□□□
□□	□□
□□□□	□□□□□□□□□□□□□□□EBV□□B-LCL□□□□□□

□□

T□□□□□NK□□□□□□□□HLA□□□□□□□□□□□□□□□□□□□CTL□□□□□□□□□□□□□□□□□□□□□HROC173□□□□□□□□□□□□□□□□

□□□

- TiBc HROC173

□□

□□	□□
□□□□	□□
□□□□	□□□□□□□
GMO□□□	GMO-S2

GMO□□□□□□□□□□□□□

GMO-S2: This B-LCL contains a stably maintained EBV episome (EBNA-1/-2/-3, LMP-1/-2). EBV is classified as risk group 2; BSL-2 containment required. This classification applies within Germany; regulations may differ elsewhere.

□□□□□□□□□□□	2

□□

□□□	□□□□
□□□□□	B□□□□□
□□□□	24□□□□48□□

□□□

□□

B-LCL-HROC173 (Cytion □□□□□□ 302039)

NCBI □□□□□	9606
□□□□□□	Not assigned

Cytion GmbH
Nikola-Tesla-Str. 3
69124 Heidelberg
Tel: +49 (0)6221 405780
info@cytion.com
cytion.com

Registered office Heidelberg
VAT ID: DE283292917
Local court Mannheim - HRB 714394
CEO / Geschäftsführer: Jonathan Steubing

Banking information
Sparkasse Heidelberg
IBAN: DE35 6725 0020 0009 2076 86
BIC: SOLADES1HDB

□□□□□□

□□□□

□□□□□EBV

□□□□□□□

□□

RPMI1640□w□2.0mM□□□□□□□□w□2.0g/L NaHCO3□Cytion article number 820700a□

□□□□□	37℃□5%CO2□□□□□□□

□□□□□□

□□□10□□□□□□FBS□□□□□□

□□□□

□□□□□□□□

□□	□□

□□□□□

□□□□□□□□□

□□□□□□□□□